Other News To Note
Tuesday, April 3, 2012
Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said it received a Department of Defense (DoD) Small Business Innovation Research grant to advance the development of a low-cost, non-invasive surface electroporation delivery device and test its use in combination with Inovio's synthetic DNA vaccines against viruses with bioterrorism potential, including hanta, puumala, arenavirus and pandemic influenza.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.